Baird Adjusts Price Target on Leap Therapeutics to $9 From $11, Maintains Outperform Rating
Leap Therapeutics Analyst Ratings
Leap Therapeutics: Promising Clinical Outcomes and Upcoming Catalysts Bolster Buy Rating
Analysts' Top Healthcare Picks: Intuitive Surgical (ISRG), Leap Therapeutics (LPTX)
Outperform Rating on Leap Therapeutics Amid Promising Gastric Cancer Trial Outcomes
Analysts Offer Insights on Healthcare Companies: Sensus Healthcare (SRTS), Outlook Therapeutics (OTLK) and Leap Therapeutics (LPTX)
Analysts Offer Insights on Healthcare Companies: Codexis (CDXS), Leap Therapeutics (LPTX) and Sutro Biopharma (STRO)
Leap Therapeutics (LPTX) Gets a Buy From Piper Sandler
Optimism High as Leap Therapeutics' Studies Suggest Potential for Significant Shareholder Value
Leap Therapeutics (LPTX) Receives a Buy From Piper Sandler
Leap Therapeutics Analyst Ratings
Financial Analyst Maintains Buy Rating for Leap Therapeutics: A Look Into Q3 2023 Results and Future Clinical Data Updates
Leap Therapeutics Analyst Ratings
Leap Therapeutics Analyst Ratings
Leap Therapeutics (LPTX) Receives a Buy From H.C. Wainwright
Leap Therapeutics (LPTX) Receives a Buy From Mizuho Securities
Raymond James Adjusts Price Target on Leap Therapeutics to $18.50 From $17, Maintains Outperform Rating
Raymond James Maintains Outperform on Leap Therapeutics, Raises Price Target to $18.5
Leap Therapeutics Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM), Apyx Medical (APYX) and Leap Therapeutics (LPTX)
No Data